Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.

Date publication

mai 2021

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33951350

Résumé

Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD). While azathioprine is an option, no data is available on ustekinumab efficacy in this situation.

Mots clés

Crohn's disease, azathioprine, postoperative recurrence, ustekinumab

Référence

United European Gastroenterol J. 2021 May 5;: